Millennium Management LLC Invests $173,000 in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Millennium Management LLC bought a new stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPTFree Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 54,186 shares of the company’s stock, valued at approximately $173,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Stifel Financial Corp acquired a new position in Checkpoint Therapeutics in the 4th quarter valued at $32,000. PUREfi Wealth LLC acquired a new position in Checkpoint Therapeutics in the fourth quarter valued at about $32,000. SBI Securities Co. Ltd. acquired a new position in Checkpoint Therapeutics in the fourth quarter valued at about $32,000. Tower Research Capital LLC TRC lifted its position in Checkpoint Therapeutics by 157.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company’s stock worth $34,000 after purchasing an additional 6,486 shares during the period. Finally, Boothbay Fund Management LLC acquired a new stake in Checkpoint Therapeutics during the fourth quarter worth about $35,000. 22.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on CKPT. D. Boral Capital restated a “buy” rating and set a $4.80 price objective on shares of Checkpoint Therapeutics in a research report on Monday, March 31st. HC Wainwright reissued a “neutral” rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. Finally, Lake Street Capital reiterated a “hold” rating and issued a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th.

Read Our Latest Research Report on CKPT

Checkpoint Therapeutics Stock Performance

NASDAQ CKPT opened at $4.26 on Friday. The firm’s fifty day moving average price is $4.13 and its two-hundred day moving average price is $3.72. The stock has a market cap of $370.71 million, a PE ratio of -2.32 and a beta of 1.18. Checkpoint Therapeutics, Inc. has a fifty-two week low of $1.80 and a fifty-two week high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPTGet Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.09). As a group, sell-side analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Checkpoint Therapeutics

In other news, CFO William Garrett Gray sold 12,322 shares of the firm’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total transaction of $49,904.10. Following the completion of the transaction, the chief financial officer now owns 1,446,322 shares of the company’s stock, valued at approximately $5,857,604.10. This trade represents a 0.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James F. Oliviero III sold 15,090 shares of the business’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total transaction of $60,963.60. Following the completion of the sale, the chief executive officer now directly owns 3,759,929 shares in the company, valued at approximately $15,190,113.16. This represents a 0.40% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

Checkpoint Therapeutics Profile

(Free Report)

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.

Recommended Stories

Want to see what other hedge funds are holding CKPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Checkpoint Therapeutics, Inc. (NASDAQ:CKPTFree Report).

Institutional Ownership by Quarter for Checkpoint Therapeutics (NASDAQ:CKPT)

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.